Medicine and Dentistry
Transplantation
95%
Hematopoietic Stem Cell
72%
Cell Transplantation
55%
Progression Free Survival
53%
Non-Hodgkin Lymphoma
51%
Overall Survival
49%
Diffuse Large B-Cell Lymphoma
46%
Hodgkin's Lymphoma
45%
Brentuximab Vedotin
36%
Hematopoietic Stem Cell Transplantation
35%
Follicular Lymphoma
32%
Peripheral T-Cell Lymphoma
27%
Autotransplantation
27%
Allotransplantation
27%
Disease
27%
Cyclophosphamide
24%
Melphalan
24%
Chimeric Antigen Receptor T-Cell
23%
Polatuzumab Vedotin
21%
Chimeric Antigen Receptor T-Cell Immunotherapy
21%
Rituximab
21%
B Cell
19%
Cytokine Release Syndrome
18%
Multiple Myeloma
18%
Thiotepa
18%
Carmustine
17%
Prednisone
17%
Doxorubicin
17%
Stem Cell Transplant
17%
Conditioning
15%
Busulfan
15%
Quality of Life
14%
Placebo
14%
Drug Megadose
14%
Pinatuzumab Vedotin
12%
Autologous Stem Cell Transplantation
12%
Chemoimmunotherapy
12%
Etoposide
11%
T Cell
11%
Autologous Hematopoietic Stem Cell Transplantation
11%
Prognostic Factor
10%
Large-Cell Lymphoma
10%
Anaplastic Large Cell Lymphoma
10%
Axicabtagene Ciloleucel
10%
Cause Specific Survival
9%
Vincristine
9%
Hematologic Malignancy
9%
Medicare
9%
Reduced Intensity Conditioning
9%
Prolymphocytic Leukemia
9%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Follicular Lymphoma
38%
Progression-free Survival
37%
Autologous Transplantation
36%
Marrow Transplantation
32%
Brentuximab Vedotin
30%
Diffuse Large B-cell Lymphoma (DLBCL)
29%
Allogeneic Transplantation
27%
Research Analysis
27%
Hodgkin Lymphoma
26%
Lymphoma Patients
26%
Overall Survival
25%
Relapsed or Refractory
25%
Non-Hodgkin Lymphoma
21%
Chimeric Antigen Receptor T Cells (CAR-T)
20%
Tisagenlecleucel
19%
Oregon
18%
Risk of Progression
18%
Busulfan
18%
Multiple Myeloma
18%
Relapse Risk
18%
University Experience
18%
OX40
18%
Cyclophosphamide
17%
Melphalan
15%
Chimeric Antigen Receptor T-cell Therapy
15%
Cytokine Release Syndrome
15%
High Risk
14%
Non-relapse Mortality
13%
Complete Response
13%
Chemoimmunotherapy
12%
CIBMTR
12%
Lymphoma
11%
Etoposide
11%
CAR T-cell Therapy
11%
Large B-cell Lymphoma
10%
Pharmacokinetics
10%
Carmustine
10%
Phase II Trial
9%
CD79B
9%
Antibody-drug Conjugate
9%
Improved Outcomes
9%
T Cells
9%
Dendritic Cells
9%
Treatment-related Mortality
9%
Colorectal Lymphoma
9%
Healthcare Resource Utilization
9%
Allogeneic HSCT
9%
Consolidation Therapy
9%
Axi-cel
9%
Immunology and Microbiology
B Cell
48%
T Cell
40%
Progression Free Survival
39%
OX40L
36%
Overall Survival
34%
Cytokine Release Syndrome
28%
Brentuximab Vedotin
27%
CD19
23%
Hematopoietic Cell
21%
Cell Transplantation
21%
Chimeric Antigen Receptor T-Cell
21%
Chimeric Antigen Receptor T-Cell Therapy
20%
Transplant Procedure
19%
Autotransplantation
18%
Allotransplantation
18%
Hematopoietic Stem Cell Transplantation
17%
Effector Cell
14%
Pharmacokinetics
13%
Autologous Hematopoietic Stem Cell Transplantation
11%
Cyclophosphamide
10%
Axicabtagene Ciloleucel
10%
Drug Megadose
10%
Dendritic Cell
10%
Bone Marrow Transplantation
9%
Chimeric Antigen Receptor
9%
Graft-Versus-Host Disease
9%
Allergic Inflammation
9%
CD134
9%
Antibody Drug Conjugate
9%
CD79B
9%
CD22
9%
Multiple Myeloma
9%
Autologous Stem Cell Transplantation
9%
Cell Interaction
9%
Stem Cell Transplant
9%
Long Term Survival
9%
Mouse
8%
Immunotherapy
7%
Survival Rate
6%
Cytotoxic T-Cell
6%
Arm
5%